These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 32403420)

  • 21. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
    Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
    Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes.
    Moses RG; Colagiuri S; Pollock C
    Australas Med J; 2014; 7(10):405-15. PubMed ID: 25379062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus.
    Fattah H; Vallon V
    Drugs; 2018 May; 78(7):717-726. PubMed ID: 29663292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors - Real-World Data.
    Gallwitz B
    Eur Endocrinol; 2018 Apr; 14(1):17-23. PubMed ID: 29922347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
    Vallon V; Thomson SC
    Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
    Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
    Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.
    Pancholia AK
    Indian Heart J; 2018; 70(6):915-921. PubMed ID: 30580866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.
    Prasanna Kumar KM; Ghosh S; Canovatchel W; Garodia N; Rajashekar S
    Indian J Endocrinol Metab; 2017; 21(1):196-209. PubMed ID: 28217522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sodium-Glucose Co-transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge.
    Provenzano M; Pelle MC; Zaffina I; Tassone B; Pujia R; Ricchio M; Serra R; Sciacqua A; Michael A; Andreucci M; Arturi F
    Front Med (Lausanne); 2021; 8():654557. PubMed ID: 34150796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology.
    Tanaka A; Node K
    J Cardiol; 2017 Mar; 69(3):501-507. PubMed ID: 28043708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.
    Marx N; McGuire DK
    Eur Heart J; 2016 Nov; 37(42):3192-3200. PubMed ID: 27153861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The renal effects of SGLT2 inhibitors and a mini-review of the literature.
    Andrianesis V; Glykofridi S; Doupis J
    Ther Adv Endocrinol Metab; 2016 Dec; 7(5-6):212-228. PubMed ID: 28203358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.
    Brunton SA
    Int J Clin Pract; 2015 Oct; 69(10):1071-87. PubMed ID: 26147213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus.
    Vinke JSJ; Heerspink HJL; de Borst MH
    Curr Opin Nephrol Hypertens; 2019 Jul; 28(4):321-327. PubMed ID: 30958403
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.